Good morning or good afternoon, ladies and gentlemen. Welcome to our first quarter 2023 results call. Before I go into the call, I would like to have the next slide and then show you the forward-looking statement slide as we will be making some forward-looking statements that are based upon our future expectations and our current expectations and assumptions. As you know, they may change in the future. Without having said that, next slide, please. I'm here with my three colleagues, Anurag Relan, our Chief Medical Officer, Stephen Toor, our Chief Commercial Officer, and Jeroen Wakkerman, our Chief Financial Officer. They will be speaking after me, and I will start with a brief introduction. Next slide, please. The next one as well.
Basically what Pharming is all about is that we are building a sustainable rare business. That rare business will be able to be funded from the positive cash flows that we continue to generate from RUCONEST. You have seen over the last quarters that these cash flows from RUCONEST have helped us to prepare and fund the launch of Joenja in the United States, and the further pipeline development that we have been doing. We're in a very favorable position. Today marks the first quarter in which we have been able to actually get Joenja approved and the last quarter where we will be reporting on sales from our single product.
Going forward, as you have seen from the press release, we will start recording sales for Joenja in the United States as well. It's an important demarcation, I would say, in the history of our company that we are now going to work to get revenues from 2 products, albeit for the time being, on only 1 major geography, the United States of America. That will soon change as well. Therefore, you can see what we're up to. We're up to successful commercialization of Joenja for APDS, and Anurag Relan will talk about that later, and additional rare disease indications where we cannot give you any specifics yet, but we will do that in the second half of the year.
Of course, we still are looking for additional projects that are in mid to late stage of development in rare diseases to actually further fill our pipeline and use and leverage further our commercialization infrastructures that we have in the US and in Europe, and that we are building up in additional markets as well. If you look at the next slide, the pipeline, you see that it is. We have now specified it in terms of the various leniolisib activities that are taking place outside the United States. You see that we have a lot of stuff on our plate and a lot of things to look forward to.
First and foremost, of course, the leniolisib approval in the European Union and the U.K., but also the pediatric projects, the Japan projects and the Canadian and Australian projects. Last but not least, the additional indications for leniolisib. It means that we can actually further down the line, have space in the capacity and our commercialization capacity to launch additional products, hence why we continue to be very active to look for additional in-licensing opportunities in other rare diseases and/or emerging acquisition opportunities in the market. Let me just go back to for a moment, go back to RUCONEST then.
That is why, you know, we are so very proud, next slide, please, of the product like RUCONEST because it helps us getting a $200 million business, if you look back last 12 months, with an outlook for single-digit revenue growth. It continues to take a unique place in the market because it's the only recombinant treatment that treats the root cause of hereditary angioedema by replacing that missing protein, that dysfunctional or missing C1 esterase inhibitor. It has proven over the years to be well-tolerated and effective. It is the second most prescribed product, detailed for acute attacks. You can't come much closer to 100% efficacy and reliability.
That's important because patients are relying on RUCONEST, where they have either a very severe form of the disease and have very high frequency attacks and cannot get by with the significantly improved prophylactic therapies. Which increasingly is the case, they actually rely on RUCONEST for being able to treat their breakthrough attacks, which, you know, almost half of the patients still suffer from in very varying frequencies. They rely on RUCONEST as their breakthrough medication. There we see an increasing use of RUCONEST. Under that, thank God for the patients with strongly improved prophylactic therapies. We can do all these successes here because we have, as I was already alluding to, a very strong commercialization infrastructure. Next slide, please. That is consisting of all these functions that you need.
You see on the slide here, all these functions that you need to be successful in commercializing, you know, rare disease assets. That is where, you know, today we look forward with very much confidence to a further success of growing the company. With the next slide, please. With the approval of leniolisib recently, we now are embarking on a growth trajectory going forward because as I said earlier, we will now be able to report on two products that are generating revenue for our company. Our, you know, our strong RUCONEST franchise that continues to show single-digit revenue as we expect for this year. On top of that, we are expecting Joenja sales from Q2 onwards to be increasing going forward. It's now time, I think, to hand over to my colleague, Dr.
Anurag Relan, our Chief Medical Officer, to dive a little bit into the APDS and into Joenja. Anurag, over to you.
Thanks, Sijmen. Before we look at the launch of Joenja, let's review a little bit about APDS. We can see it on the next slide that APDS is a rare primary immune deficiency, also known as an inborn error of immunity that was only first characterized just a little over 10 years ago in 2013. We estimate that it affects approximately 1,500 patients in some of the countries that you see listed there, and that's based on a prevalence of 1.5 per million. To date, we have already identified more than 500 of these patients across these areas. The treatment options, until recently have been quite limited for APDS patients. We'll talk a little bit about that. The treatment has been limited because it's only been focused on the symptoms of the disease.
These symptoms begin early in childhood, do not address the root cause of APDS. The signs and symptoms vary, and we'll talk a little bit about what those look like, but they vary even within a family, and this results in significant delays, especially due to the delayed onset of the diagnosis. The diagnosis itself is actually quite simple to make when the clinician thinks of it, that's really through this genetic test that can provide a definitive diagnosis. Next slide. As we see here, APDS really impacts patients in many ways. There's of course, the physical manifestations, and you see that really in the top left with the recurrent infections that these patients have, the enlarged lymph nodes and glands.
They have numerous infections that lead to damage in their lungs and a whole slew of symptoms there that you can see due to these, due to this progressive serious disease that develops early in childhood. On top of the physical manifestations, there's real impact on these patients' quality of life. Of course, there's the social aspects where they can't work or can't go to school or do their normal daily activities. There's the mental aspect of being afflicted with a chronic disease with, you know, where the treatment up till now has really been focused on the symptom, symptomatic management. Lastly, the treatment burden. Frequent hospitalizations, unnecessary surgeries, many times, numerous doctor visits just to get a diagnosis and then really being limited in terms of what can be offered.
On the next slide, we can see what causes APDS. This is due to a genetic defect that leads to this hyperactivity of this pathway, the PI3K pathway. When that pathway is overactive, that results in this dysregulated environment for the B and T cells to develop properly. When these cells of the immune system don't develop properly, you see a chain reaction set off. On the right side, you can see all of the symptoms that result as because of this hyperactive pathway leading to this immune imbalance. Of course, it's a primary immune deficiency, so you see recurrent infections. These can be in the lungs, in the upper respiratory tract, the lower respiratory tract. It can also be commonly associated with herpes viruses, especially EBV and CMV viruses. One of the hallmarks of the disease is lymphoproliferation.
What we see that as in these patients is swollen lymph nodes and enlarged spleen, and also, disruption of their lymphoid tissue across their body. They also can have, gastrointestinal manifestations. Commonly, because the immune systems are, immune system is not functioning properly, they have autoimmune issues, including cytopenias and other autoimmune disorders. As I mentioned earlier, bronchiectasis, which is a, complication in their lung, where this is irreversible, also commonly develops in these patients. The most severe manifestation and what often takes these patients' lives is the development of lymphoma due to this unchecked lymphoproliferative process and this immune imbalance that occurs as a result of this disrupted, PI3K activity. On the next slide, we can see sort of the treatment options that were available to manage these patients prior to the approval of Joenja in the U.S.
On the one hand, on the left, you can see it was limited to trying to address the immune deficiency. Using antibiotics to prevent infections, to treat infections, but also using immunoglobulin replacement therapy as a way to augment their own immune system. On the right side, you see the issues that they were faced with these patients in terms of immune dysregulation. Trying to control the immune system with steroids or other immune suppressants, including drugs like mTOR inhibitors. None of these therapies, however, were approved for APDS treatment. In the rare cases, some of these patients were given a stem cell transplant, although transplantation itself is a high-risk procedure in these patients.
On the next slide, we can see what Joenja now offers, and it's an immune modulator that addresses the root cause of this hyperactivity, hyperactive pathway, excuse me, in these patients, and is designed to treat that cause by normalizing this pathway, this PI3K delta pathway. As a result, what we see is a normal balance of the development of the immune system cells. We can see that when we measure the immature cells and the functional cells, now they progress normally through their development path. On the next slide, we can see the summary of what this Joenja approval now offers to patients. It is indicated for patients who are 12 years of age and older who have APDS. We, I'll be reviewing with you some of the randomized data, it met the randomized study met both primary endpoints.
We're also going to review some of the secondary endpoints and exploratory measures that were seen in this study. The drug was generally well-tolerated, and there weren't study withdrawals due to drug-related adverse events. On the right side, you can see some of the other data that we generated with Joenja, specifically that would have long-term data showing reductions in including discontinuations in the use of immunoglobulin replacement therapy, and as well as reductions in infection rates. These study results were consistent with what was observed in the double-blind placebo-controlled study, including long-term data on lymphadenopathy, as well as some of the immune phenotype. As Steve will report in a few minutes, we are well-positioned to hit the ground running with Joenja. Next slide. Here is a depiction of the label as well as the packaging.
On the next slide, we can see some of the data from the randomized control study. As I mentioned, Joenja met both co-primary endpoints, which saw a reduction in the lymph node size on the left, as well as an improvement in the naive B cell count compared to placebo. This strongly indicated a correction of the underlying immune defect, and you can see that when you see the size of the lymph nodes decrease relative to placebo, as well as on the right side, you can see how the naive B cell proportion increased in these patients, again, relative to placebo. Both measures were statistically significant, and these were the two co-primary endpoints in the study. Next slide.
When we look at the open label data, what we saw is over time, a reduction in the number of days that these patients had infections over the course of the year. We saw that reduce the longer that they were on Joenja. At the same time, what was observed, and this was again, spontaneous really in the study, where these, where physicians and patients were able to stop using in many cases, IRT therapy, and many of them also reduced the use of IRT therapy as the study progressed. Next slide. Now looking ahead, we have a number of other milestones later this year. Steve will report on the launch that's been started just last month.
As Sijmen mentioned, we are under review under, at Europe, and we're continuing to expect a CHMP opinion later this year with an approval 2 months later. We also expect to file in the UK later this year with an approval soon thereafter. We're also expecting to start the Japanese clinical study, which is a small study in up to 5 patients to support a regulatory submission there, and we'll be doing that in the first half of this year still. We, of course, had started earlier this year a pediatric study in children ages 4 to 11, and that is going on. We expect to start our second pediatric study in the third quarter of this year in even younger children. Next slide.
Turning now toward another program that we have that's an earlier stage program. This is the partnership with Orchard Therapeutics to develop an ex vivo autologous stem cell gene therapy for HAE. We're continuing to make progress on developing the vector here to enhance expression levels. That vector is now being tested in a number of HAE disease models in animals. We anticipate being able to provide further updates as we move toward preparing an IND filing later this year. Next slide. I'll turn it over here to Steve to give you a commercial update.
Thank you, and all right. Good morning, everybody. Over the next four slides, I'm going to provide you an overview of the Q1 RUCONEST performance and some early insights into the progress of the Joenja launch just six weeks after approval. As you're aware, there were HAE market-wide issues that impacted some government insured patients, resulting in delayed product shipments. Our internal data and external audit data show significant declines for all acute and prophylactic products. That impacted all companies serving HAE patients. The issues were resolved late in the quarter, and as effective patients started shipping, RUCONEST sales accelerated, and the product staged the highest positive return or bounce back of all the acute products in the market.
With the Q1 market-wide issues and disruption behind us, we saw good sales in March and also strong sales in April as the recovery continued. We also, of course, as the slide alludes to, see strength in the underlying business, more especially high volumes of new patient enrollments and growth in prescribing physicians. We therefore expect sales to strengthen through Q2, and we continue to forecast low single-digit revenue growth for RUCONEST in 2023. Now let's turn to the Joenja launch. As can be seen in this slide, Pharming is bringing all of its rare disease commercialization experience to bear in the US, our first of many launches on a must-win market.
We have 54 salespeople and sales leaders, and that's comprised of the RUCONEST sales team, where we think 30% of patients are treated by customers already very well served by Pharming. The new Joenja institutional team. This team focuses on central locations or centers of excellence, to which we expect the other 70% of APDS patients to either currently be treated or be referred to. Between these two teams, we have the vast majority of the APDS market covered in the U.S. Importantly for you to know, our sales colleagues are comprised of experienced, rare disease, specialty, and hospital representatives and sales leaders with launch experience and importantly, patient-finding experience. As with the RUCONEST team that successfully turned around the brand on reacquisition from Valeant, we've stocked that team with award-winning salespeople to drive a successful launch.
They're our feet on the street. They're out there identifying patients. Importantly, as you see here, we also have clinical educators to drive family mapping and family testing. This is critical because this is an autosomal dominant disease, so other members of the family are highly likely to have APDS, and it's important for them that they get access to Joenja as quickly as they can. Of course, it's an important source of new patients for Pharming. We also have a dedicated full-service concierge patient services program that ensures once a patient's diagnosed, there are zero distractions and challenges to addressing or to getting Joenja into a patient's hands. I think that's important in what is a complex market to navigate. The program covers all of the basics.
The filling of prescriptions, financial aid, and ongoing to support to ensure adherence and continued access to medication. In terms of staffing, this is where we believe we're really differentiated from many of our competitors in the rare disease space. We have care coordinators providing a single point of contact, often the same person, delivering consistent service and care and providing reassurance to patients and their families. That's versus the more traditional commoditized call center model. We have the clinical educators I've mentioned already, there to support and educate patients and caregivers. Importantly, we have clinical pharmacists that will be available 24 hours a day to process Joenja prescriptions, answer any questions patients might have, and speed up approval rates, which having these guys on team really, really allow us to happen.
Importantly, we've also partnered with PANTHERx RX, which many of you familiar with the U.S. market who you'll know. They're an excellent value partner specializing in rare and ultra-rare conditions. That gives them unique insights and really helps them to deliver for our patients in the way that they expect and Pharming expects. This dedicated program and staff should speed access to medication, minimize bureaucracy and mistakes, and cater, as I said, to the very specific needs of these patients. Next slide, please. Before I get to the early results, I just wanna talk briefly about the value proposition that, for Joenja, which Anurag articulated very clearly earlier. We should remember that Joenja is the only indicated treatment for APDS.
It's a precision medication, so when the patient tests positive, the HCP and the payer know they're prescribing and approving the right treatment for the right treatment option for the patient. Joenja's disease-modifying. It's working on the root cause of APDS, as Anurag said, for both immune deficiency and dysregulation. Pharming, therefore, is launching a product the physicians and their underserved patients need. We have, as I've outlined, hopefully the right infrastructure and services to get products in the patient's hands as quickly as possible. Let's look quickly at the progress so far. Next slide, please. I think as you all know, the launch and market preparation was rigorous and thorough, and as expected, we're off to a very good start. Our first fully reimbursed commercial shipments of Joenja occurred just two weeks after FDA approval.
To date, we've shipped to 23 patients, all on payer-approved products. About half are from the early access or open-label extension programs, and we continue to make good progress transitioning these 25 patients to paid product. The other half of those shipped patients are patients that are new to Joenja. So most of the EAP patients are enrolled on paid therapy, and we're steadily working through the OLE patients and all this while simultaneously building a new patient caseload. Importantly for the US, in the area of market access or managed care, we continue to make good progress with national and regional payers, including state Medicaid programs, to prepare for clinical review of coverage policy development. We expect to see those developed in the next 90-100 days. In the meantime, patients are being approved pretty quickly through the medical exception process.
Looking at Medicaid specifically, our teams have done an excellent job getting Joenja covered for APDS patients. We've already two-thirds of the states listing the product in just six weeks. As you can see, we're prepared, we're off to a fast and impressive start, only six weeks since we launched Joenja. I greatly look forward to updating you on Joenja launch progress later in the year when we can share the Q2 results for both RUCONEST and Joenja. With that, I'd like now to hand over to Jeroen, who'll cover the financials.
Thank you very much, Steve, good morning, good afternoon. Next slide, please. As Steve mentioned earlier, as you can see on this slide, the first quarter results were lower. That was due to the HAE market factors which impacted the entire industry. Those industry-wide factors have since resolved, and we can confirm that we've strongly recovered. If we look at the quarter, January was in line with last year, and February is where we faced headwinds. March had a strong recovery and so had April. We've almost made up all of the shortfall and expect to recover the remainder. We therefore continue to expect single-digit growth in RUCONEST revenues for 2023. On this slide, you see that the revenues in Q1 were $42.5 million.
That's 9% down on last year for the reasons I mentioned. Gross profit developed in line with that. It went down by 8% to $38.5 million. The operating costs increased from $40 million to almost $53 million, and that was on the back of leniolisib, both in R&D investments and in sales and marketing costs. Operating profit and net profit reduced, and the operating loss was $13.7 million, and the net loss $12.2 million. The short of this quarter is that the sales shifted from Q1 to Q2, and we've seen that in April. With regards to costs, we're investing in leniolisib, and obviously we haven't recorded any revenues in Q1 yet for leniolisib or JOENJA, but that will change in Q2.
We then go to the next slide, please, on the cost development. You see that we are continuing to invest in the launch of Joenja. You look at the longer term trends over the quarters that are shown here, starting with the R&D brackets at the bottom, we see a reduction in quarterly R&D costs in Q2, that is because of reduced investment in the transgenic platform. You see a uptick again in Q1 this year because of leniolisib. Looking at the G&A, general & admin cost, developments, we've seen a slight growth per quarter over the last last quarters, which basically means investment ahead of company growth. Q1 was higher than than last year, Q1 of 2023, lower than previous years.
The big number in Q4, by the way, the $17.6 that you see is because of an impairment cost of a building. That's not a repetitive cost. The marketing and sales cost, the biggest bracket, we've seen a quarterly growth of marketing and sales cost in 2022, with more investments in the Joenja launch, especially obviously in Q4 last year. I should note that the marketing and sales expenses for the U.S. launch are high in this period, also in Q3. Going forward, we will see an increase in the marketing and sale cost in other key markets, namely Europe and the UK, in the trailing quarters as we prepare for launch.
To get an indication of OPEX levels for the remainder of the year, therefore for full year, the Q4 of 2022 and the Q1 2023 OPEX levels are good indicators, albeit it may increase moderately. If we go to the next slide, it's about the cash flow. The cash went down from $207 million to $185 million at the end of Q1. The key reason is the net cash flows used in operating activities. The cash loss was $10.2 million from operations. Working capital increased by $12 million, that was mainly because of an increase in inventory and debtors, the latter was because of phasing.
The cash flows used in financing activities is due to regular interest and lease costs, and we had some positive foreign exchange effects, bringing the cash to $185 million. The outlook on the next slide. We continue to expect low single-digit growth in RUCONEST revenues for the full year. Joenja was approved in the first quarter on the 24th of March by the FDA, and we have been commercializing in the U.S. since early April 2023. We expect in Europe a positive CHMP opinion in the second half of this year and the marketing authorization to follow two months later. Subject to the positive outcome of the CHMP review, we will file for U.K. approval with the MHRA.
We will continue to invest in future growth and to accelerate it, and that will obviously be focused on the Joenja launch. We will provide further details of our plans to develop leniolisib in additional indications in the second half of this year. To finish off with, we will continue to look for late stage opportunities in rare diseases, be it in in-licensing or in potential acquisitions. We're still open for investments very much in that area. With that, this concludes the presentation, and I would like to go to the next slide and open up for questions and answers to any of the people attending the call from the Barnet side. Thank you very much.
Thank you. If you would like to ask a question, please press star followed by 1 on your telephone keypad now. If you change your mind, please press star followed by 2. When preparing to ask your question, please ensure your line is unmuted locally. Our first question comes from Alistair Campbell of RBC. Alistair, your line is now open. Please go ahead.
Thanks so much. Yeah, a couple of questions, please. First of all, on Rybka, just so I understand what's going on here. Is this a feature of basically sales which would have.
Is there actually genuinely a shortfall in sales? Just trying to understand, you know, if the disruption hadn't happened, would you be more likely to get maybe something like mid-single rather than low single digits? Question two is, I know it's very, very early, but just to get a bit of insight into the patients you've put onto Joenja. At this stage, do you have sort of a sense of the severity of those patients, like, are they sort of across the spectrum of severity or do they tend to be around. If I can push my luck, you've got 23 patients on therapy now. What do you think a good number would be to be sort of exiting, twenty-
You were breaking up. You had a third question, Alistair?
Sorry. Third question was, you know, given you've got 23 patients on Joenja now, what do you think would be a good exit number for the end of the year?
Okay. Thanks. Let me answer the last one, and I'll go back to Stephen on the first two questions. We don't give... As you can appreciate, it's early days and we don't give any sort of, you know, forward-looking statements on what we think is a reasonable number. I think it's too early. But you obviously agree with us that already having 23 patients on paid therapy and many more in the enrollment process, gives you a good indication that we're prepared to launch very carefully. You also heard Stephen talking about how well we're progressing with getting the reimbursement sorted for Joenja. you know, let's keep it at this.
Obviously, over the coming quarters, we will continue to report on those patient numbers. Going forward, we will, you know, give some more indications as and when we see a clear trend arising. That's the answer to question number 3. I'm sorry, I can't go in any further detail. I would like to go back to Stephen about your question with regards to RUCONEST sales in the first quarter, and the if there's any sort of differentiation in the severity of your Joenja patients. Steve, over to you.
Thank you, Sijmen. In terms of the RUCONEST sales, I really think our guidance wouldn't have changed. There was disruption in the 1st quarter which pushed patients out a little in terms of delivery of product. At this point we're playing catch up. I think the guidance would remain the same as it was in mid to late March when we last gave it, which is expect low single-digit revenue growth. In terms of severity of patients, I don't have deep insights. What I would hypothesize, and perhaps invite Anurag Relan if he's got anything to add, is that these are patients largely already identified. At least half of them are in EAP, or in the open label extension.
They were identified, therefore they were exhibiting symptoms and were at least at the moderate end of the scale.
Yeah, I think we can see.
Does that hopefully answer the question?
Yeah. That's clear. Thank you.
Oh, sorry. I was just gonna say...
Go ahead, Anurag.
I think the key point is that there was a mix of patients here. We had patients who were in the study that have now started Joenja commercial, paid product. We have patients who were in the Expanded Access Program, and we also have naive patients. These are patients who are not in the Expanded Access Program or in the study, who are now receiving Joenja, leniolisib for the first time.
Okay. Does that answer your question, Alistair?
That's good. Thank you.
All right. Thank you.
Our next question comes from Sushila Hernandez from Oppenheimer. Sushila, your line is now open. Please go ahead.
Yes, thank you for taking my question. On RUCONEST. Could you expand on the reimbursement disruptions affecting the HAE market? Since Takeda showed an increase in Takhzyro sales this quarter, what were the circumstances that led to a more pronounced disruption on your end? A second question. You mentioned that you expect quarterly fluctuations from RUCONEST sales, so what are the drivers behind these fluctuations that you are anticipating? Thank you.
Thanks, Sushila. I hand this question back to Stephen.
Certainly. Yeah. I mean, the disruption was primarily in the government sector. And some of those patients saw disruptions to their co-pays and the cost of accessing medication, which is what resolved itself as we went through the quarter. I can't comment to the company to the sales obviously, of other companies. What I will say is, if you look at Symphony data, for example, and specifically their Metys database, you see that every company saw significant disruption in Q1. I can't comment to that, but I can say that the disruption was specifically within the government-insured patient sector, and it resolved satisfactorily and all those patients, certainly on the RUCONEST side, are now receiving their medications.
The other question, Sushila?
Yes. Indeed, you mentioned that you expect quarterly fluctuations of RUCONEST sales. What are these drivers behind these fluctuations that you anticipate?
Apologies, I missed that. It's the... As named, it tends to be honestly more a combination of seasonal and just the length of the selling months. For example, we tend to see some dips during the significant U.S. holidays, so Independence Day, Thanksgiving, around Christmas. It's not. And also during the holiday season as well, where patients will stock in ahead of going on vacation and then, and then not order as much during the periods when they're away. It's. And I think it's the fact we're not, we're not driven by the law of large numbers, right? We have a certain amount of patients, and when the change in their ordering patterns changes-
You see changes in our order rates and therefore quarterly fluctuations. There's nothing of real significance beyond that.
Okay, thank you.
Thank you.
As a reminder, if you would like to ask a question, please press star followed by 1 on your telephone keypad now. If you change your mind, please press star followed by 2.
Does this mean there's no more questions?
Our next question comes from Simon Scholes of First Berlin. Simon, your line is now open. Please go ahead.
Yes, hello.
Simon.
You've taken the decision to discontinue Pompe. I remember a few years ago, you expected, your product under development to have quite a benign side effect profile compared with the current market leader. I was wondering if you could comment on your decision to discontinue, given your expectation of that positive side effect profile and also, whether you took the decision to discontinue maybe because it would have taken too long to bring the product to market, if that played a role?
Yeah. It's a good question, Simon. I think there's still significant unmet medical needs in Pompe. That's not necessarily the case. We did not simply see the differentiating features that we felt confident enough to go forward with investing in the project. Therefore, we basically, you know, decided to stop and abandon this project. There's also, of course, new developments on the horizon where other than protein replacement therapies, for instance, the GYS1 receptor antagonists are being developed as we speak. We thought it was appropriate to stop this, bearing, you know, but not seeing any of the differentiating features. That was the main reason to make the decision.
Okay, thanks very much.
Any more questions, Simon?
Just a quick reminder. If you would like to ask a question, please press star followed by one on your telephone keypad now. No further questions. I'll hand back to the management team for any closing remarks.
Okay, thank you very much. Yeah, ladies and gentlemen, thanks for attending this first quarter results conference. As I was saying in the beginning of the call, this first quarter marks a clear demarcation. We got our second product approved here. We have a established commercialization infrastructure in the U.S., and we're building that up in Europe. We're preparing rigorously for the launch of many of us outside of the U.S.
I hope we, you agree that we are off to a very good launch with regards to Joenja in the United States because of the fact that we already have these 23 patients on pay therapy, you know, within 6 weeks after launch, which is not a given in rare diseases, and there are many more are already in the process. We look forward to Very much forward, I would say, to coming back to you next quarter and report on not 1, but 2 products that will drive our revenue. Of course, last but not least, we remain confident. I would like to again say that we remain confident in the robustness of our RUCONEST business going forward.
Thank you very much, for being here again, and we look forward to updating you again on the next quarter results in the beginning of August. Thank you. Goodbye.